Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norditropin Simplexx Acceptance in Children with GHD
NCT01563926Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2000
- Primary completion
- Oct 2002
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), Turner syndrome (TS) and chronic kidney disease (CKD), sponsored by Novo Nordisk. Primary endpoint: Patient acceptance of the new liquid growth hormone formulation. Started Oct 2000; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)Turner syndrome (TS)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01563926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563926.